A widespread deferoxamine-mediated iron-uptake system in Vibrio vulnificus

Journal of Infectious Diseases

Volumn 196, Issue 10, 2007, Pages 1537-1545

  Kim, Choon Mee ^a   Park, Yong Jin ^a   Shin, Sung Heui ^a  

^a Chosun University College of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

DEFEROXAMINE; TRANSFERRIN; BACTERIAL DNA; BACTERIAL PROTEIN; BACTERIAL RNA; IRON CHELATING AGENT; IRON UPTAKE REGULATION PROTEIN, BACTERIA; IRON-UPTAKE REGULATION PROTEIN, BACTERIA; PRIMER DNA; REPRESSOR PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; BACTERIAL GENE; BACTERIAL GROWTH; BACTERIAL STRAIN; CONTROLLED STUDY; DESA GENE; GENE EXPRESSION; GROWTH INHIBITION; GROWTH STIMULATION; IRON TRANSPORT; NONHUMAN; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RISK FACTOR; VIBRIO VULNIFICUS; GENE EXPRESSION REGULATION; GENETICS; HUMAN; METABOLISM; POLYMERASE CHAIN REACTION;

BACTERIAL PROTEINS; DEFEROXAMINE; DNA PRIMERS; DNA, BACTERIAL; GENE EXPRESSION REGULATION, BACTERIAL; HUMANS; IRON CHELATING AGENTS; POLYMERASE CHAIN REACTION; REPRESSOR PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, BACTERIAL; VIBRIO VULNIFICUS;

EID: 38449118832     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/523108     Document Type: Article

References (45)

1. Park SD, Shon HS, Joh NJ. Vibrio vulnificus septicemia in Korea: clinical and epidemiologic findings in seventy patients. J Am Acad Dermatol 1991; 24:397-403.
2. Gulig PA, Bourdage KL, Starks AM. Molecular pathogenesis of Vibrio vulnificus. J Microbiol 2005; 43:118-31.
3. Kushner JP. Hypochromic anemias. In: Wyngaarden JB, Smith LH, eds. Cecil textbook of medicine. 18 ed. Vol 1. Philadelphia: WB Saunders, 1988:892-900.
4. Marx JJM. Iron and infection: competition between host and microbes for a precious element. Best Pract Res Clin Haematol 2002; 15:411-26.
5. Bullen JJ, Rogers HJ, Sparlding PB, Ward G. Iron and infection: the heart of the matter. FEMS Immunol Med Microbiol 2005; 43:325-30.
6. Brown JS, Ogunniyi AD, Woodrow MC, Holden DW, Paton JC. Immunization with components of two iron-uptake ABC transporters protects mice against systemic infection with Streptococcus pneumoniae. Infect Immun 2001; 69:6702-6.
7. Kontoghiorghes GJ, Weinberg ED. Iron: mammalian defense mechanisms, mechanisms of disease, and chelation therapy approaches. Blood Rev 1995; 9:33-45.
8. Wright AC, Simpson LM, Oliver JD. Role of iron in the pathogenesis of Vibrio vulnificus infections. Infect Immun 1981; 34:503-7.
9. Brennt CE, Wright AC, Dutta SK, Morris JG Jr. Growth of Vibrio vulnificus in serum from alcoholics: association with high transferrin iron saturation. J Infect Dis 1991; 164:1030-2.
10. Bullen JJ, Sparlding PB, Ward CG, Gutteridge JM. Hemochromatosis, iron and septicemia caused by Vibrio vulnificus. Arch Intern Med 1991; 151:1606-9.
11. Starks AM, Schoeb TR, Tamplin ML, et al. Pathogenesis of infection by clinical and environmental strains of Vibrio vulnificus in iron-dextrantreated mice. Infect Immun 2000; 68:5785-93.
12. Weiss G. Iron and immunity: a double edged sword. Eur J Clin Invest 2002; 32:70-8.
13. van Asbeck BS, Marx JJ, Struyvenberg A, Verhoef J. Functional defects in phagocytic cells from patients with iron overload. J Infect 1984; 8:232-40.
14. Ong ST, Ho ZJS, Ho B, Ding JL. Iron-withholding strategy in innate immunity. Immunobiology 2006; 211:295-314.
15. Kawase T, Miyoshi S, Sultan Z, Shinoda S. Regulation system of protease production in Vibrio vulnificus. FEMS Microbiol Lett 2004; 240:55-9.
16. Shin SH, Sun HY, Park RY, et al. Vibrio vulnificus metalloprotease VvpE has no direct effect on the iron-assimilation from human holotransferrin. FEMS Microbiol Lett 2005; 247:221-9.
17. Kim CM, Park RY, Park JH, et al. Vibrio vulnificus vulnibactin, but not metalloprotease VvpE, is essentially required for iron-uptake from human holotransferrin. Biol Pharm Bull 2006; 29:911-8.
18. Sun HY, Han SI, Choi MH, Kim SJ, Kim CM, Shin SH. Vibrio vulnificus metalloprotease VvpE has no direct effect on iron-uptake from human hemoglobin. J Microbiol 2006; 44:537-47.
19. Litwin CM, Rayback TW, Skinner J. Role of catechol siderophore synthesis in Vibrio vulnificus. Infect Immun 1996; 64:2824-38.
20. Webster ACD, Litwin CM. Cloning and characterization of vuuA, a gene encoding Vibrio vulnificus ferric vulnibactin receptor. Infect Immun 2000; 68:526-34.
21. Kim CM, Park RY, Choi MH, Sun HY, Shin SH. Ferrophilic characteristics of Vibrio vulnificus and potential usefulness of iron chelation therapy. J Infect Dis 2007; 195:90-8.
22. Olivieri NF, Brittenham GM. Iron-chelating therapy and the treatment of thalassemia. Blood 1997; 89:739-61.
23. Aso H, Miyoshi S, Nakao H, Okamoto K, Yamamoto S. Induction of an outer membrane protein of 78 kDa in Vibrio vulnificus in the presence of desferrioxamine B under iron-limiting conditions. FEMS Microbiol Lett 2002; 212:65-70.
24. Tanabe T, Takata N, Naka A, et al. Identification of an AraC-like regulator required for induction of the 78-kDa ferrioxamine B receptor in Vibrio vulnificus. FEMS Microbiol Lett 2005; 249:309-14.
25. Miller V, Mekalanos JJ.Anovel suicide vector and its use in construction of insertion mutations: osmoregulation of outer membrane proteins and virulence determinants in Vibrio cholerae requires toxR. J Bacteriol 1988; 170:2575-83.
26. Ditta G, Stanfield DC, Corbin D, Helinski DR. Broad host range DNA cloning system for gram-negative bacteria: construction of a gene bank of Rhizobium meliloti. Proc Natl Acad Sci USA 1980; 77:7347-51.
27. McGee K, Horstedt P, Milton DL. Identification and characterization of additional flagellin genes from Vibrio anguillarum. J Bacteriol 1996; 178:5188-98.
28. Staskawicz B, Dahlbeck D, Keen K, Napoli C. Molecular characterization of cloned avirulence genes from race 0 and race 1 of Pseudomonas syringae pv. Glycinea. J Bacteriol 1987; 169:5789-94.
29. Herrero M, de Lorenzo V, Timmis KN. Transposon vectors containing non-antibiotic resistance selection markers for cloning and stable chromosomal insertion of foreign genes in gram-negative bacteria. J Bacteriol 1990; 172:6568-72.
30. Choi MH, Park RY, Sun HY, et al. Suppression and inactivation of Vibrio vulnificus hemolysin in cirrhotic ascites, a human ex vivo experimental system. FEMS Immunol Med Microbiol 2006; 47:226-32.
31. Leong SA, Neilands JB. Siderophore production by phytopathogenic microbial species. Arch Biochem Biophys 1982; 218:351-9.
32. Stookey LI. Ferrozine - a new spectrophotometric reagent for iron. Anal Chem 1970; 42:779-81.
33. Makey DG, Seal US. The detection of four molecular forms of human transferrin during the iron binding process. Biochem Biophys Acta 1976; 453:250-6.
34. Falkow S. Molecular Koch's postulates applied to bacterial pathogenicity - a personal recollection 15 years later. Nat Rev Microbiol 2004; 2:67-72.
35. Simpson LM, Oliver JD. Siderophore production by Vibrio vulnificus. Infect Immun 1983; 41:644-9.
36. Litwin CM, Byrne BL. Cloning and characterization of an outer membrane protein of Vibrio vulnificus required for heme utilization: regulation of expression and determination of the gene sequence. Infect Immun 1998; 66:3134-41.
37. Tanabe T, Naka A, Aso H, et al. A novel aerobactin utilization cluster in Vibrio vulnificus with a gene involved in the transcription regulation of the iutA homologue. Microbiol Immunol 2005; 49:823-34.
38. Hoffbrand AV, Al-Refaie F, Davis B, et al. Long-term trial of deferiprone in 51 transfusion-dependent iron overloaded patients. Blood 1998; 91:295-300.
39. van Asbeck BS, Marcelis JH, Struyvenberg A, et al. Inhibition of bacterial multiplication by the iron chelator deferoxamine: potentiating effect of ascorbic acid. Eur J Clin Microbiol 1983; 2:426-31.
40. van Asbeck BS, Marcelis JH, van Kats JH, et al. Synergy between the iron chelator deferoxamine and the antimicrobial agents gentamicin, chloramphenicol, cefalothin, cefotiam and cefsulodin. Eur J Clin Microbiol 1983; 2:432-8.
41. Lesic B, Foulon J, Carniel E. Comparison of the effect of deferiprone versus deferoxamine on growth and virulence of Yersinia enterocolitica. Antimicrob Agents Chemother 2002; 46:1741-5.
42. Sebulsky MT, Hohnstein D, Hunter MD, Heinrichs DE. Identification and characterization of a membrane permease involved in iron-hydroxamate transport in Staphylococcus aureus. J Bacteriol 2000; 182:4394-400.
43. Berner I, Konetschny-Rapp S, Jung G, Winkelmann G. Characterization of ferrioxamine E as the principal siderophore in Erwinia herbicola (Enterbacter agglomerans). Biol Metals 1988; 1:51-6.
44. Reissbrod R, Rabsch W, Chapeaurouge A, Jung G, Winkelmann G. Isolation and identification of ferrioxamine G and E in Hafnia alvei. Biol Metals 1990; 3:54-60.
45. Park RY, Choi MH, Sun HY, Shin SH. Production of catecholsiderophore and utilization of transferrin-bound iron in Bacillus cereus. Biol Pharm Bull 2005; 28:1132-5.